Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Forestviewon Apr 23, 2021 9:04am
91 Views
Post# 33054098

RE:RE:RE:Why this talk

RE:RE:RE:Why this talkI do have to agree with these comments.  Dan needs to hit the dates he commits to.  Get a Project Manager or two in there to hold these folks accountable (I'm oversimplifying, I know).  But, the point I'm making is this has gone on long enough.  And COVID is not longer an excuse.  Commit to what you've said, so we are not giving the FUD's and the other manipulators the ammo they need to prey on retail investors.  Lots of great things coming, but if you can't execute, the market won't care, and the stock price will suffer.  

woundedknee wrote: If new investors haven't done their DD on Antibe yet then I would suggest Dan is not doing a very good job. And by the way, I thought we were paying an IR firm thousands a month to do just that. Attract new investors, that is. So if it has been turned over to Dan let's terminate the IR contract and save a few bucks.


<< Previous
Bullboard Posts
Next >>